Rare and Orphan Diseases - Global Neurology Academy

1-16 of 71

Evaluating Delayed Presentations of Subarachnoid Hemorrhage
Evaluating Delayed Presentations of Subarachnoid Hemorrhage
NeuroFrontiers
Evaluating Delayed Presentations of Subarachnoid Hemorrhage
Jay Max Findlay
- Jay Max Findlay
Spotting the Warning Signs of Subarachnoid Hemorrhage
Spotting the Warning Signs of Subarachnoid Hemorrhage
NeuroFrontiers
Spotting the Warning Signs of Subarachnoid Hemorrhage
Jay Max Findlay
- Jay Max Findlay
The Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
The Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
NeuroFrontiers
The Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
Jay Max Findlay
- Jay Max Findlay
The Recovery Trajectory of Subarachnoid Hemorrhage
The Recovery Trajectory of Subarachnoid Hemorrhage
NeuroFrontiers
The Recovery Trajectory of Subarachnoid Hemorrhage
Jay Max Findlay
- Jay Max Findlay
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiers
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS; Kaitlin Batley, MD
- Alexandria May, PharmD, BCPS
- Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiers
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP; Bethany Lussier, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bethany Lussier, MD
Examining the Global Genetic Prevalence of TK2d
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiers
Examining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP; Austin Larson, MD
- Brian P. McDonough, MD, FAAFP
- Austin Larson, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiers
Friedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Unpacking the Genetics of Friedreich’s Ataxia
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiers
Unpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiers
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
- Ryan Quigley
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses

Prev
1
2
3
4
5
Next

1/5